Schedules of Controlled Substances Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol (-)-delta-9-trans- tetrahydrocannabinol (delta-9-THC) in Schedule II. Final rule.
This final rule adopts without changes an interim final rule with request for comments published in the Federal Register on March 23, 2017. On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug product consisting of dronabinol (-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC) oral solution. The Drug Enforcement Administration (DEA) maintains FDA-approved products of oral solutions containing dronabinol in schedule II of the Controlled Substances Act.